Acute Respiratory Distress Syndrome (ARDS) ❖ 500,000 patients in US/year❖ ARDS mortality rate ~30-40%❖ The majority of COVID deaths are due to ARDS❖ US ARDS market size $5B annually❖ ARDS growing at a rate of ~3% per year, accelerated by COVID-19 pandemic❖ Market Opportunity❖ No FDA-Approved Therapies for ARDS Links to:News and Press Releases Related to ARDS Learn More about ARDSLearn More About e-Namptor™ Platform and ALT-100 mAb
